| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Shah Nikita | Executive Vice President | C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BLVD., BRIDGEWATER | /s/ Denis Butkovic, Attorney-in-Fact | 14 Nov 2025 | 0001738061 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AMRX | Class A Common Stock | Options Exercise | $99,910 | +36,331 | +25% | $2.75 | 182,734 | 12 Nov 2025 | Direct | |
| transaction | AMRX | Class A Common Stock | Options Exercise | $262,694 | +95,525 | +52% | $2.75 | 278,259 | 12 Nov 2025 | Direct | |
| transaction | AMRX | Class A Common Stock | Sale | $1,571,724 | -131,856 | -47% | $11.92 | 146,403 | 12 Nov 2025 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AMRX | Stock Option (Right to Buy) | Options Exercise | $0 | -36,331 | -100% | $0.000000 | 0 | 12 Nov 2025 | Class A Common Stock | 36,331 | $2.75 | Direct | F2 |
| transaction | AMRX | Stock Option (Right to Buy) | Options Exercise | $0 | -95,525 | -100% | $0.000000 | 0 | 12 Nov 2025 | Class A Common Stock | 95,525 | $2.75 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.85 to $12.02 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| F2 | This option is fully vested. |